Menaquinone analogs inhibit growth of bacterial pathogens

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5432-5437

  Schlievert, Patrick M ^a,b   Merriman, Joseph A ^a   Salgado Pabón, Wilmara ^a   Mueller, Elizabeth A ^a   Spaulding, Adam R ^a   Vu, Bao G ^a   Chuang Smith, Olivia N ^b   Kohler, Petra L ^b   Kirby, John R ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINONE; ANTIBIOTIC AGENT; COENZYME Q3; GLYCEROL MONOLAURATE; MENADIONE; MENAQUINONE; MENAQUINONE DERIVATIVE; PHYTOMENADIONE; REACTIVE OXYGEN METABOLITE; UBIDECARENONE; UBIQUINONE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BORDETELLA BRONCHISEPTICA; CELL MEMBRANE; CONTROLLED STUDY; DRUG POTENTIATION; ESCHERICHIA COLI; GARDNERELLA VAGINALIS; IN VITRO STUDY; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BACTERIAL PROTEINS; CELL MEMBRANE; DRUG SYNERGISM; EXOTOXINS; HUMANS; LAURATES; MONOGLYCERIDES; RABBITS; REACTIVE OXYGEN SPECIES; REPRESSOR PROTEINS; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; VITAMIN K 2;

EID: 84885908612     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01279-13     Document Type: Article

References (40)

1. Cone LA, Woodard DR, Schlievert PM, Tomory GS. 1987. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N. Engl. J. Med. 317:146-149.
2. McCormick JK, Yarwood JM, Schlievert PM. 2001. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 55: 77-104.
3. Schlievert PM, Gocke JE, Deringer Jr. 1993. Group B streptococcal toxic shock-like syndrome: report of a case and purification of an associated pyrogenic toxin. Clin. Infect. Dis. 17:26-31.
4. Spaulding AR, Salgado-Pabon W, Kohler PL, Horswill AR, Leung DY, Schlievert PM. 2013. Staphylococcal and streptococcal superantigen exotoxins. Clin. Microbiol. Rev. 26:422-447.
5. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, Kaplan E. 1989. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N. Engl. J. Med. 321:1-7.
6. Davis JP, Chesney PJ, Wand PJ, LaVenture M. 1980. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N. Engl. J. Med. 303:1429-1435.
7. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, Anderson RL, Hill DL, Broome CV, Band JD, Fraser DW. 1980. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N. Engl. J. Med. 303:1436-1442.
8. Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP. 1981. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shocksyndrome Staphylococcus aureus isolates. Lancet i:1017-1021.
9. Schlievert PM, Shands KN, Dan BB, Schmid GP, Nishimura RD. 1981. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J. Infect. Dis. 143:509-516.
10. Marrack P, Kappler J. 1990. The staphylococcal enterotoxins and their relatives. Science 248:705-711.
11. Kotzin BL, Leung DY, Kappler J, Marrack P. 1993. Superantigens and their potential role in human disease. Adv. Immunol. 54:99-166.
12. Georgellis D, Kwon O, Lin EC. 2001. Quinones as the redox signal for the arc two-component system of bacteria. Science 292:2314-2316.
13. Novick RP. 2003. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol. Microbiol. 48:1429-1449.
14. Pragman AA, Schlievert PM. 2004. Virulence regulation in Staphylococcus aureus: the need for in vivo analysis of virulence factor regulation. FEMS Immunol. Med. Microbiol. 42:147-154.
15. Schlievert PM, Case LC, Nemeth KA, Davis CC, Sun Y, Qin W, Wang F, Brosnahan AJ, Mleziva JA, Peterson ML, Jones BE. 2007. Alpha and beta chains of hemoglobin inhibit production of Staphylococcus aureus exotoxins. Biochemistry 46:14349-14358.
16. Schlievert PM, Kelly JA. 1984. Clindamycin-induced suppression of toxic-shock syndrome-associated exotoxin production. J. Infect. Dis. 149: 471.
17. Schlievert PM, Peterson ML. 2012. Glycerol monolaurate antibacterial activity in broth and biofilm cultures. PLoS One 7:e40350. doi:10.1371/journal. pone.0040350.
18. Projan SJ, Brown-Skrobot S, Schlievert PM, Vandenesch F, Novick RP. 1994. Glycerol monolaurate inhibits the production of beta-lactamase, toxic shock toxin-1, and other staphylococcal exoproteins by interfering with signal transduction. J. Bacteriol. 176:4204-4209.
19. Schlievert PM. 2007. Chitosan malate inhibits growth and exotoxin production of toxic shock syndrome-inducing Staphylococcus aureus strains and group A streptococci. Antimicrob. Agents Chemother. 51:3056 -3062.
20. MacDonald KL, Osterholm MT, Hedberg CW, Schrock CG, Peterson GF, Jentzen JM, Leonard SA, Schlievert PM. 1987. Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness. JAMA 257:1053-1058.
21. Centers for Disease Control and Prevention. 1999. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus -Minnesota and North Dakota, 1997-1999. JAMA 282:1123-1125.
22. Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner DJ, Long D, Bubeck Wardenburg J, Schneewind O, Otto M, Deleo FR. 2011. Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J. Infect. Dis. 204:937-941.
23. Bae T, Schneewind O. 2006. Allelic replacement in Staphylococcus aureus with inducible counter-selection. Plasmid 55:58-63.
24. Lin YC, Anderson MJ, Kohler PL, Strandberg KL, Olson ME, Horswill AR, Schlievert PM, Peterson ML. 2011. Proinflammatory exoprotein characterization of toxic shock syndrome Staphylococcus aureus. Biochemistry 50:7157-7167.
25. Blomster-Hautamaa DA, Schlievert PM. 1988. Preparation of toxic shock syndrome toxin-1. Methods Enzymol. 165:37-43.
26. Yarwood JM, McCormick JK, Paustian ML, Kapur V, Schlievert PM. 2002. Repression of the Staphylococcus aureus accessory gene regulator in serum and in vivo. J. Bacteriol. 184:1095-1101.
27. Rodriguez CE, Shinyashiki M, Froines J, Yu RC, Fukuto JM, Cho AK. 2004. An examination of quinone toxicity using the yeast Saccharomyces cerevisiae model system. Toxicology 201:185-196.
28. Yarwood JM, McCormick JK, Schlievert PM. 2001. Identification of a novel two-component regulatory system that acts in global regulation of virulence factors of Staphylococcus aureus. J. Bacteriol. 183:1113-1123.
29. Wakeman CA, Hammer ND, Stauff DL, Attia AS, Anzaldi LL, Dikalov SI, Calcutt MW, Skaar EP. 2012. Menaquinone biosynthesis potentiates haem toxicity in Staphylococcus aureus. Mol. Microbiol. 86:1376-1392.
30. Anzaldi LL, Skaar EP. 2011. The evolution of a superbug: how Staphylococcus aureus overcomes its unique susceptibility to polyamines. Mol. Microbiol. 82:1-3.
31. Shibata H, Suzuki K, Kobayashi S. 2007. Menaquinone reduction by an HMT2-like sulfide dehydrogenase from Bacillus stearothermophilus. Can. J. Microbiol. 53:1091-1100.
32. Jamieson DJ. 1992. Saccharomyces cerevisiae has distinct adaptive responses to both hydrogen peroxide and menadione. J. Bacteriol. 174: 6678-6681.
33. Flattery-O'Brien J, Collinson LP, Dawes IW. 1993. Saccharomyces cerevisiae has an inducible response to menadione which differs from that to hydrogen peroxide. J. Gen. Microbiol. 139:501-507.
34. Vetter SM, Schlievert PM. 2007. The two-component system Bacillus respiratory response A and B (BrrA-BrrB) is a virulence factor regulator in Bacillus anthracis. Biochemistry 46:7343-7352.
35. Pragman AA, Yarwood JM, Tripp TJ, Schlievert PM. 2004. Characterization of virulence factor regulation by SrrAB, a two-component system in Staphylococcus aureus. J. Bacteriol. 186:2430-2438.
36. Delaune A, Poupel O, Mallet A, Coic YM, Msadek T, Dubrac S. 2011. Peptidoglycan crosslinking relaxation plays an important role in Staphylococcus aureus WalKR-dependent cell viability. PLoS One 6:e17054. doi: 10.1371/journal.pone.0017054.
37. Schlievert PM, Deringer JR, Kim MH, Projan SJ, Novick RP. 1992. Effect of glycerol monolaurate on bacterial growth and toxin production. Antimicrob. Agents Chemother. 36:626-631.
38. Schlievert PM, Strandberg KL, Brosnahan AJ, Peterson ML, Pambuccian SE, Nephew KR, Brunner KG, Schultz-Darken NJ, Haase AT. 2008. Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use. Antimicrob. Agents Chemother. 52:4448-4452.
39. Strandberg KL, Peterson ML, Lin YC, Pack MC, Chase DJ, Schlievert PM. 2010. Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus. Antimicrob. Agents Chemother. 54:597-601.
40. Strandberg KL, Peterson ML, Schaefers MM, Case LC, Pack MC, Chase DJ, Schlievert PM. 2009. Reduction in Staphylococcus aureus growth and exotoxin production and in vaginal interleukin 8 levels due to glycerol monolaurate in tampons. Clin. Infect. Dis. 49:1711-1717.